Scarica l'app Stockscreener
3.06
0.33%
-0.010
Pre-mercato:
3.06
Panoramica
Notizia
Cronologia dei prezzi
Perché EVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$3.07
Aprire:
$3.07
Volume 24 ore:
63,539
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.09B
Reddito:
$890.87M
Utile/perdita netta:
$-115.85M
Rapporto P/E:
-9.3836
EPS:
-0.3261
Flusso di cassa netto:
$-104.29M
1 W Prestazione:
-1.92%
1M Prestazione:
+16.35%
6M Prestazione:
+3.03%
1 anno Prestazione:
-28.84%
Intervallo 1D:
$3.04
$3.11
Intervallo di 1 settimana:
$3.03
$3.30
Portata 52W:
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.06 | 1.09B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
16.36 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.84 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.98 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.67 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
569.88 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Ripresa | H.C. Wainwright | Buy |
| 2026-02-03 | Iniziato | Berenberg | Buy |
| 2025-04-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2024-08-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-04-04 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-01-07 | Ripresa | Citigroup | Neutral |
Mostra tutto
Evotec Se Adr Borsa (EVO) Ultime notizie
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com Canada
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Canada
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com India
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec appoints Ingrid Müller as chief operating officer - Investing.com
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal - Investing.com
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec's B2B Partner Search Initiative: Unlocking Strategic Collaborations in Drug Discovery for Nor - AD HOC NEWS
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 - ChartMill
Evotec appoints Ashiq Khan as chief commercial officer - Investing.com
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer - ChartMill
Evotec SE Stock: Drug Discovery Leader Faces Restructuring Challenges Ahead of Key Earnings - AD HOC NEWS
Evotec SE stock faces pressure amid biotech sector volatility and partnership updates - AD HOC NEWS
Evotec SE Stock Faces Pressure Amid Biotech Sector Headwinds and Pipeline Updates in Q1 2026 - AD HOC NEWS
Evotec Se Adr Azioni (EVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
8.16%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):